<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131035">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396148</url>
  </required_header>
  <id_info>
    <org_study_id>A6181196</org_study_id>
    <secondary_id>2011-002008-33</secondary_id>
    <nct_id>NCT01396148</nct_id>
  </id_info>
  <brief_title>A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor</brief_title>
  <official_title>A Phase I/ii Study Of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with
      sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be
      studied in these patients. In addition, tumor responses and overall survival will be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics- Estimated steady-state maximum plasma concentration (Cmax) for sunitinib and its active metabolite SU012662</measure>
    <time_frame>Weeks 1-18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- estimated area under the plasma concentration versus time curve from time zero to 24 hours post dose (AUC24) for sunitinib and its active metabolite SU012662</measure>
    <time_frame>Weeks 1-18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- estimated oral clearance (CL/F) for sunitinib</measure>
    <time_frame>Weeks 1-18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- Observed single-dose maximum plasma concentration (Cmax) for sunitinib and its active metabolite SU012662</measure>
    <time_frame>Weeks 1-18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- Observed time to Cmax (tmax) for sunitinib and its active metabolite SU012662</measure>
    <time_frame>Weeks 1-18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- Observed area under the plasma concentration versus time curve from time zero to 8 hours post dose (AUC8) for sunitinib and its active metabolite SU012662</measure>
    <time_frame>Weeks 1-18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 2 years after study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 2 years after study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 2 years after study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 2 years after study enrollment</measure>
    <time_frame>up to 2 years after study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated sunitinib plasma concentration at which 50% of the maximum effect for each selected efficacy parameter (eg, sum of largest diameters for target tumors) is observed</measure>
    <time_frame>up to 2 years after study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated sunitinib plasma concentration at which 50% of the maximum effect for each selected safety endpoint (eg, absolute neutrophil count) is observed</measure>
    <time_frame>up to 2 years after study enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Children with GIST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>children ages 6yrs-&lt;18yrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young adults with GIST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>young adults ages 18yrs-&lt;21 yrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate dose escalation</intervention_name>
    <description>sunitinib starting dose will be 15mg/m^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).</description>
    <arm_group_label>Children with GIST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>sunitinib 50mg daily on Schedule 4/2</description>
    <arm_group_label>Young adults with GIST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of GIST.

          -  Patients must have demonstrated either disease progression or intolerance to imatinib
             mesylate, have non-mutant Stem Cell Factor Receptor gene (KIT) GIST, or cannot obtain
             imatinib in their country

          -  Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable
             disease.

        Exclusion Criteria:

          -  Current treatment with another investigational agent.

          -  Prior sunitinib treatment.

          -  Prior therapy with known risk for cardiovascular complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Viera Bajciova, Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>613 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>FN Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav</name>
      <address>
        <city>Brno</city>
        <zip>656 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de La Timone, Hopital enfants</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital d'Enfants de la Timone</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181196&amp;StudyName=A%20Study%20of%20Sunitinib%20In%20Young%20Patients%20With%20Advanced%20Gastrointestinal%20Stromal%20Tumor</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>July 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children and young adults with GIST</keyword>
  <keyword>sunitinib malate</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>tumor response</keyword>
  <keyword>overall survival</keyword>
  <keyword>tumor KIT mutation status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
